MOUNTAIN VIEW, Calif., June 17, 2013 \/PRNewswire\/ --In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin reagent for direct supply to biomedical researchers. <\/p>\n
RetroNectin reagent is designed to enable efficient retroviral transduction of genes into hematopoietic stem cells as well as lymphocytes and other blood cells. The RetroNectin method has been recognized as a standard gene transduction method in ex vivo gene therapy around the world. In addition, RetroNectin reagent has another remarkable feature that can also be useful for cell therapies: during the expansion culture of human T lymphocytes, RetroNectin reagent helps to increase proportion of nave T cells. This RetroNectin induced T cell method has already become available as a cancer therapy in three Japanese clinics under technical support from Takara Bio. <\/p>\n
Takara Bio is the exclusive supplier of RetroNectin reagent, a recombinant human fibronectin fragment developed in 1995 by Takara Bio in collaboration with Indiana University. It has been used in 68 gene therapy clinical trials in 44 institutes and hospitals in 10 countries to date. <\/p>\n
Previously, access to clinical-grade RetroNectin reagent required a Material Transfer Agreement (MTA) between a research institution and Takara Bio. Researchers may now submit direct orders to Clontech or local Takara Bio subsidiaries for RetroNectin (GMP), which is manufactured as a quality-assured product according to guidelines for Good Manufacturing Practice (GMP). The Drug Master File for RetroNectin (GMP) has been filed with the U.S. Food and Drug Administration. In a recent study published in Science Translational Medicine in March 2013, scientists at Memorial Sloan-Kettering Cancer Center reported an immunotherapy strategy for the treatment of five adult patients with acute lymphoblastic leukemia. Each patient's T cells were extracted, altered by introduction of DNA that would cause the cells to attack tumor cells, and infused back into the patient's bloodstream. According to researchers, all patients achieved tumor eradication and complete remission. RetroNectin reagent was used during T cell transduction. <\/p>\n
Corresponding author Dr. Renier J. Brentjens said, \"It was very clear to us even 10 years ago that the use of RetroNectin coated plates markedly, massively improved gene transfer.\" Dr. Brentjens continued, \"The methodologies that many of us now use have been developed over a number of years. Once you have a system that works, you become very reliant and dependent on those reagents.\" <\/p>\n
\"RetroNectin reagent has become a standard reagent for many gene transfer protocols worldwide,\" said Carol Lou, General Manager of Clontech. \"We are sure that such direct access to RetroNectin (GMP) without MTA execution will make this reagent available much more easily to any scientists or clinicians interested in RetroNectin clinical applications, which aligns with Takara Bio's mission of contributing to the health of mankind through gene therapy.\" <\/p>\n
About Clontech Laboratories, Inc.Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include the Living Colors fluorescent proteins; high-performance qPCR and PCR reagents (including theTaKaRa Ex Taq,TaKaRa LA Taq, Titanium, and Advantage enzymes); RT enzymes and SMART library construction kits; the innovative In-Fusion cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit http:\/\/www.clontech.com<\/a>. <\/p>\n About Takara Bio Inc.Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available athttp:\/\/www.takara-bio.com. <\/p>\n For more information, contact: <\/p>\n Lorna Neilson, Ph.D. Director, Business Development Clontech Laboratories, Inc. A TakaraBio Company lorna_neilson@clontech.com<\/a> (650) 919-7372 <\/p>\n <\/p>\n The rest is here: <\/p>\n Clinical Grade RetroNectin\u00ae Reagent Available To Support Gene Therapy Clinical Research<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" MOUNTAIN VIEW, Calif., June 17, 2013 \/PRNewswire\/ --In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc Continue reading